李启靖

2017-06-27

李启靖, 分子免疫学家,杜克大学医学院免疫学系终身教授。李启靖在免疫学方向的工作师从Mark Davis教授,起步于T细胞受体的灵敏性研究,确立了T细胞受体识别的最小单位和限速步骤,并将正在萌芽常态中的microRNA研究引入免疫学,发现了miR-181a分子是决定T细胞受体识别和免疫反应灵敏度的核心内源因子并阐明了其调控对象和分子机制。自2008年在杜克大学组建自己的实验室以来,以microRNA为探索工具以及免疫调控靶点,以自身免疫疾病和肿瘤免疫治疗为临床背景,开展了一系列的基础及转化研究。目前其工作聚焦于T细胞的功能调控,以及T细胞与肿瘤免疫微环境的相互作用。在转化医学的前沿,致力于免疫新技术研发,T细胞的工程化改造,为临床免疫治疗及治疗过程中的免疫监控不断提供新方法及新策略。

 Dr. Qi-Jing Li is a molecular immunologist at Duke University Medical Center. He was trained by Dr. Mark Davis at Stanford University, where he initiated his scientific career as a T cell biologist. Dr. Li’s early research focused on the sensitivity of T cell antigen receptor (TCR). He made a series of contributions in determining the minimal subunit and rate-limiting step of TCR activation. His pioneer work introduced microRNA into the immunology field and determined that miR-181a as an intrinsic master regulator for T cell sensitivity. In 2008, Dr. Li started up his own lab at Duke, where he continued his research in the field of autoimmunity and tumor immunology. Taking microRNAs as tools for discovery and targets for immunomodulation, his work has been focusing on regulatory mechanisms during T cell functional differentiation, as well as interplays between T cells and tumor microenvironment. On the front of translational medicine, Dr. Li has been continuously developing new technology platforms, engineering new cell therapy tools, and, devoting them to clinical stage for immunotherapy and immune monitoring.


上一篇:何维
下一篇:邹 锋
Powered by 飞色网络